Search Results

You are looking at 1 - 10 of 12 items for :

  • "Multikinase inhibitors" x
  • Thyroid cancer - clinical x
Clear All
Daniela Dias Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Daniela Dias in
Google Scholar
PubMed
Close
,
Inês Damásio Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Inês Damásio in
Google Scholar
PubMed
Close
,
Pedro Marques Endocrinology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte (CHULN), Lisbon, Portugal

Search for other papers by Pedro Marques in
Google Scholar
PubMed
Close
,
Helder Simões Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Helder Simões in
Google Scholar
PubMed
Close
,
Ricardo Rodrigues Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
Close
,
Branca Maria Cavaco Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed
Close
, and
Valeriano Leite Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Nova Medical School: Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal

Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Close

developed for advanced thyroid carcinoma. Multikinase inhibitors have a non-negligible toxicity that may decrease the patient’s quality of life. Novel insights GEMOX (gemcitabine plus oxaliplatin) may have a role in patients with

Open access
Carla Gambale Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Carla Gambale in
Google Scholar
PubMed
Close
,
Alessandro Prete Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Close
,
Chiara Romei Department of Diagnostic Imaging, Unit of Radiology, Pisa University Hospital, Pisa, Italy

Search for other papers by Chiara Romei in
Google Scholar
PubMed
Close
,
Alessandro Celi Department of Surgery, Medicine, Molecular Biology and Critical Care, Respiratory Pathophysiology Unit, Pisa University Hospital, Pisa, Italy

Search for other papers by Alessandro Celi in
Google Scholar
PubMed
Close
,
Rossella Elisei Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Close
, and
Antonio Matrone Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Close

advanced/metastatic ( 1 ). According to European Medicines Agency (EMA) indications, two multikinase inhibitors (MKIs) (i.e. vandetanib and cabozantinib) and one highly selective RET inhibitor (i.e. selpercatinib) have been approved for the treatment of

Open access
Elisa Minaldi Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Elisa Minaldi in
Google Scholar
PubMed
Close
,
Virginia Cappagli Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Virginia Cappagli in
Google Scholar
PubMed
Close
,
Loredana Lorusso Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Close
,
Laura Valerio Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Laura Valerio in
Google Scholar
PubMed
Close
,
Carlotta Giani Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Carlotta Giani in
Google Scholar
PubMed
Close
,
Matilde Viglione Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Matilde Viglione in
Google Scholar
PubMed
Close
,
Laura Agate Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Laura Agate in
Google Scholar
PubMed
Close
,
Eleonora Molinaro Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Close
,
Antonio Matrone Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Close
, and
Rossella Elisei Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Close

, interquartile range; MKI, multikinase inhibitors; TC, thyroid carcinoma. Sorafenib The group treated with sorafenib was represented by 74 patients, of which 40/74 (54.1%) were females and 34/74 (45.9%) were males. The mean age at the starting of

Open access
Ana Piñar-Gutiérrez UGC Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, España

Search for other papers by Ana Piñar-Gutiérrez in
Google Scholar
PubMed
Close
,
Ana R Romero-Lluch UGC Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, España

Search for other papers by Ana R Romero-Lluch in
Google Scholar
PubMed
Close
,
Suset Dueñas-Disotuar UGC Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, España

Search for other papers by Suset Dueñas-Disotuar in
Google Scholar
PubMed
Close
,
Irene de Lara-Rodríguez UGC Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, España

Search for other papers by Irene de Lara-Rodríguez in
Google Scholar
PubMed
Close
,
María Ángeles Gálvez-Moreno Servicio de Endocrinología, Hospital Universitario Reina Sofía, Córdoba, España

Search for other papers by María Ángeles Gálvez-Moreno in
Google Scholar
PubMed
Close
,
Tomás Martín-Hernández Servicio de Endocrinología, Hospital Universitario Virgen Macarena, Sevilla, España

Search for other papers by Tomás Martín-Hernández in
Google Scholar
PubMed
Close
,
Jorge García-Alemán Servicio de Endocrinología, Hospital Universitario Virgen de la Victoria, Málaga, España

Search for other papers by Jorge García-Alemán in
Google Scholar
PubMed
Close
,
Guillermo Martínez-de Pinillos Servicio de Endocrinología, Hospital Universitario Virgen de Valme, Sevilla, España

Search for other papers by Guillermo Martínez-de Pinillos in
Google Scholar
PubMed
Close
, and
Elena Navarro-González UGC Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, España

Search for other papers by Elena Navarro-González in
Google Scholar
PubMed
Close

/Hematology 2005 56 365 – 378 . ( https://doi.org/10.1016/j.critrevonc.2005.03.011 ) 9 Navarro-Gonzalez E . Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine-resistant differentiated thyroid

Open access
Carla Colombo Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Carla Colombo in
Google Scholar
PubMed
Close
,
Daniele Ceruti Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Close
,
Simone De Leo Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy

Search for other papers by Simone De Leo in
Google Scholar
PubMed
Close
,
Grzegorz Bilo Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Search for other papers by Grzegorz Bilo in
Google Scholar
PubMed
Close
,
Matteo Trevisan Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Close
,
Noemi Giancola Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Noemi Giancola in
Google Scholar
PubMed
Close
,
Claudia Moneta Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Close
,
Gianfranco Parati Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Search for other papers by Gianfranco Parati in
Google Scholar
PubMed
Close
,
Luca Persani Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Luca Persani in
Google Scholar
PubMed
Close
, and
Laura Fugazzola Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Close

Introduction Multikinase inhibitors (MKIs) with strong anti-angiogenetic action are frequently used for the treatment of advanced radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) or medullary thyroid cancers (MTCs) ( 1 , 2

Open access
Grace Segall Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Grace Segall in
Google Scholar
PubMed
Close
,
Ravinder Singh Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Ravinder Singh in
Google Scholar
PubMed
Close
,
Min-Hua Jen Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Min-Hua Jen in
Google Scholar
PubMed
Close
,
Isaac Sanderson Adelphi Real World, Bollington, UK

Search for other papers by Isaac Sanderson in
Google Scholar
PubMed
Close
,
Alex Rider Adelphi Real World, Bollington, UK

Search for other papers by Alex Rider in
Google Scholar
PubMed
Close
,
Katie Lewis Adelphi Real World, Bollington, UK

Search for other papers by Katie Lewis in
Google Scholar
PubMed
Close
, and
Urpo Kiiskinen Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Urpo Kiiskinen in
Google Scholar
PubMed
Close

MTC for whom treatment with systemic therapy is planned ( 12 ). Systemic therapies in advanced or metastatic MTC (aMTC) include multikinase inhibitors (MKIs) and selective RET inhibitors ( 12 , 13 ). ESMO treatment guidelines from April 2022

Open access
Andrew G Gianoukakis The Lundquist Institute at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Torrance, California, USA

Search for other papers by Andrew G Gianoukakis in
Google Scholar
PubMed
Close
,
Jennifer H Choe Department of Medicine, Duke University Medical Center/Duke Cancer Institute, Durham, North Carolina, USA

Search for other papers by Jennifer H Choe in
Google Scholar
PubMed
Close
,
Daniel W Bowles Division of Medical Oncology, University of Colorado, Aurora, Colorado, USA

Search for other papers by Daniel W Bowles in
Google Scholar
PubMed
Close
,
Marcia S Brose Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

Search for other papers by Marcia S Brose in
Google Scholar
PubMed
Close
,
Lori J Wirth Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA

Search for other papers by Lori J Wirth in
Google Scholar
PubMed
Close
,
Taofeek Owonikoko Winship Cancer Institute of Emory University, Atlanta, Georgia, USA

Search for other papers by Taofeek Owonikoko in
Google Scholar
PubMed
Close
,
Svetlana Babajanyan Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA

Search for other papers by Svetlana Babajanyan in
Google Scholar
PubMed
Close
, and
Francis P Worden Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA

Search for other papers by Francis P Worden in
Google Scholar
PubMed
Close

Gild ML Tsang VHM Clifton-Bligh RJ & Robinson BG . Multikinase inhibitors in thyroid cancer: timing of targeted therapy . Nature Reviews. Endocrinology 2021 17 225 – 234 . ( https://doi.org/10.1038/s41574-020-00465-y ) 10 Brose MS Smit

Open access
Pepijn van Houten Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Pepijn van Houten in
Google Scholar
PubMed
Close
,
James Nagarajah Roentgeninstitut Duesseldorf, Duesseldorf, Germany
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by James Nagarajah in
Google Scholar
PubMed
Close
,
Janneke E W Walraven Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Janneke E W Walraven in
Google Scholar
PubMed
Close
,
Martin Jaeger Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Martin Jaeger in
Google Scholar
PubMed
Close
,
Adriana C H van Engen-van Grunsven Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Adriana C H van Engen-van Grunsven in
Google Scholar
PubMed
Close
,
Johannes W Smit Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Johannes W Smit in
Google Scholar
PubMed
Close
, and
Romana T Netea-Maier Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Search for other papers by Romana T Netea-Maier in
Google Scholar
PubMed
Close

included RAI-refractory NMTC patients with different histological subtypes and genotypes, the multikinase inhibitor sorafenib did not reinduce RAI uptake in RAI-refractory NMTC patients ( 23 ). So, while there are some valid options for redifferentiation

Open access
Haruhiko Yamazaki Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama City, Kanagawa, Japan
Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Haruhiko Yamazaki in
Google Scholar
PubMed
Close
,
Kiminori Sugino Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Kiminori Sugino in
Google Scholar
PubMed
Close
,
Ryohei Katoh Department of Pathology, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Ryohei Katoh in
Google Scholar
PubMed
Close
,
Kenichi Matsuzu Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Kenichi Matsuzu in
Google Scholar
PubMed
Close
,
Wataru Kitagawa Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Wataru Kitagawa in
Google Scholar
PubMed
Close
,
Mitsuji Nagahama Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Mitsuji Nagahama in
Google Scholar
PubMed
Close
,
Aya Saito Department of Surgery, Yokohama City University School of Medicine, Yokohama City, Kanagawa, Japan

Search for other papers by Aya Saito in
Google Scholar
PubMed
Close
, and
Koichi Ito Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Koichi Ito in
Google Scholar
PubMed
Close

. Available from: https://www.nccn.org/home (accessed 18 March 2024)). Anti-angiogenic drugs are multikinase inhibitors, including sorafenib, lenvatinib, and cabozantinib. Targeted agents include selective RET inhibitors (selpercatinib or pralsetinib) for

Open access
Junyu Tong Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Junyu Tong in
Google Scholar
PubMed
Close
,
Maomei Ruan Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

Search for other papers by Maomei Ruan in
Google Scholar
PubMed
Close
,
Yuchen Jin Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Close
,
Hao Fu Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Hao Fu in
Google Scholar
PubMed
Close
,
Lin Cheng Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Lin Cheng in
Google Scholar
PubMed
Close
,
Qiong Luo Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

Search for other papers by Qiong Luo in
Google Scholar
PubMed
Close
,
Zhiyan Liu Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Zhiyan Liu in
Google Scholar
PubMed
Close
,
Zhongwei Lv Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

Search for other papers by Zhongwei Lv in
Google Scholar
PubMed
Close
, and
Libo Chen Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Libo Chen in
Google Scholar
PubMed
Close

-refractory differentiated thyroid carcinoma may be helpful to discover the pathological basis of radioiodine-refractory differentiated thyroid carcinoma. What we should not ignore is that most multikinase inhibitors do not bring significant overall survival benefit but

Open access